V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220020901 | 220008842 | 1.69 | null | Palliative (P) | 2017-03-05 | 2017-06-08 | Cytarabine intrathecal | 02 | N | 220033249 | CYTARABINE INTRATHECAL |
| 220020902 | 220008845 | 1.71 | 71.6 | Adjuvant (A) | 2016-04-24 | 2016-07-15 | CARBOPLATIN + PACLITAXEL | N | N | 220033250 | CARBOPLATIN + PACLITAXEL |
| 220020903 | 220008858 | 1.69 | 83.7 | Curative (C) | 2017-08-07 | 2017-08-17 | GEMTUZUMAB OZOGAMICIN | N | N | 220033294 | CLOFARABINE + CYTARABINE |
| 220020904 | 220008866 | 1.6 | 57 | Curative (C) | null | 2017-03-01 | Carboplatin + Etoposide iv&po | N | N | 220033348 | CARBOPLATIN + ETOPOSIDE |
| 220020905 | 220008868 | 1.83 | 69 | Curative (C) | 2014-10-10 | 2015-02-15 | GEMTUZUMAB OZOGAMICIN | null | N | 220033375 | METHOTREXATE |
| 220020906 | 220014752 | 1.5 | 57 | null | 2016-04-21 | 2016-10-09 | PACLITAXEL | N | N | 220033397 | PACLITAXEL |
| 220020907 | 220008874 | 1.6 | 56 | Curative (C) | 2015-11-28 | 2015-12-04 | Cytarabine intrathecal | N | N | 220033438 | CYTARABINE INTRATHECAL |
| 220020908 | 220008876 | 1.44 | 93.8 | null | 2015-01-15 | 2015-01-15 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 220033442 | UKALL2014 |
| 220020909 | 220008882 | 1.78 | 106 | Curative (C) | 2019-01-16 | 2019-01-17 | Mitox + Tretinoin Spanish Course 3 | null | null | 220033449 | MITOXANTRONE |
| 220020910 | 220008886 | 1.68 | 59 | Curative (C) | 2018-12-10 | 2019-04-29 | Irinotecan + Modified De Gramont | N | N | 220033473 | UKALL2014 |
| 220020911 | 220008891 | 1.74 | 51 | Palliative (P) | 2016-06-06 | 2016-08-17 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 220033475 | ALEMTUZUMAB |
| 220020912 | 220008894 | null | 71.4 | Curative (C) | 2017-02-02 | 2017-02-02 | Cytarabine intrathecal | null | null | 220033484 | CYTARABINE INTRATHECAL |
| 220020913 | 220008898 | 1.5 | 28.3 | Curative (C) | 2016-06-17 | 2016-06-26 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | N | 220033508 | PONATINIB |
| 220020914 | 220008907 | 1.69 | 58.1 | Palliative (P) | 2017-12-27 | 2017-12-27 | Oxaliplatin + Modified de Gramont | null | null | 220033515 | PONATINIB |
| 220020915 | 220021913 | 1.77 | 43.85 | Palliative (P) | 2016-11-19 | 2016-11-29 | Dacarbazine | N | null | 220033520 | EC |
| 220020916 | 220014770 | null | 45 | Palliative (P) | 2016-05-27 | 2016-05-27 | Alemtuzumab+Busulfan+CyclophosphMUD | N | null | 220033551 | FLUDARABINE |
| 220020917 | 220014772 | null | null | Curative (C) | 2018-10-30 | 2018-10-30 | Alemtuzumab + Cyclophos TBI Allo | null | null | 220033567 | CETUXIMAB |
| 220020918 | 220014774 | 1.59 | 64.75 | Curative (C) | 2016-03-02 | 2016-03-03 | GCLAC | null | N | 220033571 | BUSULPHAN + FLUDARABINE |
| 220020919 | 220014778 | 1.78 | 71.6 | Disease modification (D) | 2016-12-10 | 2017-01-19 | Kadcyla | N | null | 220033680 | CYTARABINE IT + METHOTREXATE |
| 220020920 | 220018081 | null | 110.2 | Palliative (P) | 2017-01-31 | 2017-03-06 | TIP | N | null | 220033681 | MACE |
| 220020921 | 220014781 | null | null | Curative (C) | 2016-02-03 | 2016-03-30 | Alemtuzumab + Cyclophos TBI Allo | 99 | null | 220033699 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220020922 | 220014781 | 2 | 68.45 | Curative (C) | 2016-03-03 | 2016-03-05 | LIPOSOMAL CYTARABINE | N | N | 220033699 | FIGARO TRIAL |
| 220020923 | 220021583 | 1.77 | 79.8 | Palliative (P) | 2015-01-14 | 2015-01-14 | TEMOZOLOMIDE | N | N | 220033717 | THALIDOMIDE |
| 220020924 | 220008959 | 1.75 | 69 | Curative (C) | 2017-08-05 | 2017-10-12 | Folfirinox | N | N | 220033807 | DABRAFENIB |
| 220020925 | 220008968 | 1.7 | null | Curative (C) | 2018-07-22 | 2018-07-30 | Capecitabine + Oxaliplatin 21day | 2 | N | 220033808 | GCLAC |
| 220020926 | 220008973 | null | null | Curative (C) | null | 2014-01-08 | Sorafenib | N | N | 220033816 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220020927 | 220020992 | 1.65 | 89 | Curative (C) | null | 2016-04-11 | GCLAC | N | N | 220033832 | CISPLATIN |
| 220020928 | 220009011 | 1.73 | 89.9 | Curative (C) | 2016-07-31 | 2016-10-10 | CYTARABINE + FLUDARABINE | N | N | 220033965 | MERCAPTOPURINE |
| 220020929 | 220009021 | null | 67.3 | Not known (9) | 2014-10-29 | 2014-10-29 | MITOXANTRONE + TRETINOIN | 01 | N | 220033988 | INTERFERON |
| 220020930 | 220018094 | 1.67 | 100 | Palliative (P) | 2016-05-29 | 2018-08-25 | CISPLATIN + FLUOROURACIL | N | N | 220033997 | PACKER INDUCTION VINCRISTINE + RT |
| 220020931 | 220009028 | 1.72 | 71.8 | Curative (C) | 2017-07-16 | 2017-12-26 | Capecitabine | 02 | N | 220034002 | MITOXANTRONE + TRETINOIN |
| 220020932 | 220009032 | 1.63 | null | Disease modification (D) | 2016-10-29 | 2016-11-30 | Cytarabine+Methotrexate Intrathecal | N | N | 220034022 | CETUXIMAB |
| 220020933 | 220019934 | null | 58.5 | Curative (C) | 2017-11-13 | 2017-11-13 | Cisplatin + Etoposide po&iv 3 day | 99 | 2 | 220034035 | FIGARO TRIAL |
| 220020934 | 220009046 | null | null | Disease modification (D) | 2015-02-03 | 2015-02-04 | MACE | N | null | 220034070 | BUSULFAN + FLUDARABINE |
| 220020935 | 220009049 | 1.78 | 102.4 | Curative (C) | 2015-04-25 | 2015-05-20 | Sorafenib | Y | null | 220034079 | INTERFERON |
| 220020936 | 220009052 | null | 76.3 | Curative (C) | 2014-10-01 | 2014-10-01 | QUASAR 2 TRIAL | 01 | N | 220034081 | ARSENIC TRIOXIDE |
| 220020937 | 220009061 | 0 | 87 | Curative (C) | null | 2017-01-05 | Capecitabine (21 day) + Irinotecan | N | N | 220034115 | MIDAC |
| 220020938 | 220009067 | null | 116.3 | Curative (C) | null | 2014-11-08 | Cytarabine+Methotrexate Intrathecal | N | null | 220034117 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN |
| 220020939 | 220009082 | null | null | Curative (C) | 2018-09-21 | 2018-10-04 | Cytarabine+Methotrexate Intrathecal | N | null | 220034164 | MACE |
| 220020940 | 220009086 | null | 48.8 | Curative (C) | null | 2016-10-04 | LENALIDOMIDE | 2 | N | 220034194 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220020941 | 220009091 | null | 62 | Disease modification (D) | 2016-11-08 | 2017-02-02 | DABRAFENIB + TRAMETINIB | 02 | N | 220034218 | LENALIDOMIDE |
| 220020943 | 220009104 | -1 | 29 | Curative (C) | 2017-05-19 | 2017-08-08 | CYTARABINE + FLUDARABINE + IDARUBICIN | null | null | 220034277 | CAPECITABINE |
| 220020944 | 220019941 | 1.71 | 83.3 | Curative (C) | 2015-08-18 | 2016-06-12 | Busulfan + Cyclophos Conditioning | N | N | 220034302 | CARFILZOMIB |
| 220020945 | 220014863 | 1.69 | 79 | Curative (C) | 2014-08-25 | 2014-08-25 | MidAC | N | N | 220034334 | FIGARO TRIAL |
| 220020946 | 220009119 | 1.73 | 16 | Palliative (P) | 2015-02-02 | 2015-10-16 | AML LI-1 Trial | 01 | N | 220034346 | OSIMERTINIB |
| 220020947 | 220009125 | 1.63 | null | null | 2015-06-30 | 2015-10-07 | CYCLOPHOSPHAMIDE + THALIDOMIDE | N | N | 220034356 | CARBOPLATIN |
| 220020948 | 220014869 | 1.69 | 104.499 | Adjuvant (A) | null | 2018-02-09 | FIGARO TRIAL | 01 | null | 220034364 | TRASTUZUMAB EMTANSINE |
| 220020949 | 220009133 | 1.69 | 68 | Curative (C) | 2017-08-05 | 2017-08-05 | BUSULFAN + CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220034423 | THALIDOMIDE |
| 220020950 | 220009136 | 1.74 | 23.8 | Disease modification (D) | null | 2018-10-12 | Cisplatin 7 day | 01 | N | 220034424 | FIGARO TRIAL |
| 220020951 | 220009141 | 1.75 | 14.1 | Curative (C) | 2016-02-06 | 2016-02-25 | VINORELBINE | N | N | 220034425 | IPO |